{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T16:35:18Z","timestamp":1717000518583},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00105-019-4402-z","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T12:02:35Z","timestamp":1554724955000},"page":"367-370","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-Laminin-332-Schleimhautpemphigoid mit irreversiblem okul\u00e4rem und tracheobronchialem Befall"],"prefix":"10.1007","volume":"70","author":[{"given":"F. M.","family":"Syring","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kasperkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"4402_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","volume":"34","author":"AR Ahmed","year":"2016","unstructured":"Ahmed AR, Nguyen T, Kaveri S et al (2016) First line treatment of pemphigus vulgaris with a\u00a0novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a\u00a0seven year follow-up. Int Immunopharmacol 34:25\u201331","journal-title":"Int Immunopharmacol"},{"key":"4402_CR2","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/S0140-6736(00)04971-0","volume":"357","author":"CA Egan","year":"2001","unstructured":"Egan CA, Lazarova Z, Darling TN et al (2001) Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 357:1850\u20131851","journal-title":"Lancet"},{"key":"4402_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00105-017-4089-y","volume":"69","author":"MM Holtsche","year":"2018","unstructured":"Holtsche MM, Zillikens D, Schmidt E (2018) Schleimhautpemphigoid. Hautarzt 69:67\u201383","journal-title":"Hautarzt"},{"key":"4402_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","volume":"136","author":"F H\u00fcbner","year":"2016","unstructured":"H\u00fcbner F, Recke A, Zillikens D et\u00a0al (2016) Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J\u00a0Invest Dermatol 136:2495\u20132498","journal-title":"J Invest Dermatol"},{"key":"4402_CR5","first-page":"E24","volume":"98","author":"E Wilder","year":"2016","unstructured":"Wilder E, Fernandez MP, Krejci-Manwaring J (2016) Mucous membrane pemphigoid involving the trachea and bronchi: an extremely rare and life-threatening presentation. Cutis 98:E24\u2013E27","journal-title":"Cutis"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-4402-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-019-4402-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-4402-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T23:24:40Z","timestamp":1586215480000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-019-4402-z"}},"subtitle":["Versp\u00e4tete Diagnosestellung einer schweren bull\u00f6sen Autoimmunerkrankung"],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4402"],"URL":"https:\/\/doi.org\/10.1007\/s00105-019-4402-z","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"8 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.M.\u00a0Syring, D.\u00a0Zillikens, E.\u00a0Schmidt und M.\u00a0Kasperkiewicz geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}